BG102669A - Метод за лечение и фармацевтичен състав - Google Patents

Метод за лечение и фармацевтичен състав Download PDF

Info

Publication number: BG102669A
Authority: BG; Bulgaria
Prior art keywords: phenyl; sodium; loratadine; leukotriene antagonist; composition according
Prior art date: 1996-02-08

Application number

BG102669A

Other languages

Bulgarian (bg)

English (en)

Inventor

Sven-Erik Dahlen

Edward Scolnick

Original Assignee

Merck & Co. Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-02-08

Filing date

1998-08-05

Publication date

1999-04-30

1996-04-29 Priority claimed from GBGB9608927.1A external-priority patent/GB9608927D0/en

1998-08-05 Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.

1999-04-30 Publication of BG102669A publication Critical patent/BG102669A/bg

Links

238000000034 method Methods 0.000 title claims abstract description 12
239000008194 pharmaceutical composition Substances 0.000 title claims description 6
239000003199 leukotriene receptor blocking agent Substances 0.000 claims abstract description 12
206010020751 Hypersensitivity Diseases 0.000 claims abstract description 6
206010061218 Inflammation Diseases 0.000 claims abstract description 5
230000007815 allergy Effects 0.000 claims abstract description 5
230000004054 inflammatory process Effects 0.000 claims abstract description 5
208000026935 allergic disease Diseases 0.000 claims abstract description 4
JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims description 11
229960003088 loratadine Drugs 0.000 claims description 11
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 9
239000002552 dosage form Substances 0.000 claims description 9
239000011734 sodium Substances 0.000 claims description 9
229910052708 sodium Inorganic materials 0.000 claims description 9
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
239000000203 mixture Substances 0.000 claims description 7
-1 3- (2- (6,7-difluoro-2-quinolinyl) ethenyl) phenyl Chemical group 0.000 claims description 6
KVVDRQDTODKIJD-UHFFFAOYSA-N 2-cyclopropylacetic acid Chemical compound OC(=O)CC1CC1 KVVDRQDTODKIJD-UHFFFAOYSA-N 0.000 claims description 4
YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 claims description 4
208000006673 asthma Diseases 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 3
YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 claims description 3
LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical compound [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 claims description 3
229960001951 montelukast sodium Drugs 0.000 claims description 3
229960004583 pranlukast Drugs 0.000 claims description 3
UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 claims description 3
159000000000 sodium salts Chemical class 0.000 claims description 3
229960004764 zafirlukast Drugs 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 2
UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims 4
229960005127 montelukast Drugs 0.000 claims 4
125000000446 sulfanediyl group Chemical group *S* 0.000 claims 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000003826 tablet Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000008213 purified water Substances 0.000 description 2
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960001021 lactose monohydrate Drugs 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229940080780 loratadine 10 mg Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
229940106779 montelukast 10 mg Drugs 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000007787 solid Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BG102669A 1996-02-08 1998-08-05 Метод за лечение и фармацевтичен състав BG102669A (bg)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US1132896P	1996-02-08	1996-02-08
GBGB9608927.1A GB9608927D0 (en)	1996-04-29	1996-04-29	Method of treatment and pharmaceutical composition
PCT/US1997/001799 WO1997028797A1 (en)	1996-02-08	1997-02-04	Method of treatment and pharmaceutical composion

Publications (1)

Publication Number	Publication Date
BG102669A true BG102669A (bg)	1999-04-30

Family

ID=26309231

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG102669A BG102669A (bg)	1996-02-08	1998-08-05	Метод за лечение и фармацевтичен състав

Country Status (19)

Country	Link
EP (1)	EP1014972A4 (is)
JP (1)	JPH11504044A (is)
KR (1)	KR19990082367A (is)
CN (1)	CN1210465A (is)
AU (1)	AU732671B2 (is)
BG (1)	BG102669A (is)
BR (1)	BR9707369A (is)
CA (1)	CA2245162A1 (is)
CZ (1)	CZ248798A3 (is)
EE (1)	EE9800234A (is)
IL (1)	IL125446A0 (is)
IS (1)	IS4805A (is)
NO (1)	NO983641L (is)
NZ (1)	NZ331160A (is)
PL (1)	PL328074A1 (is)
SK (1)	SK105698A3 (is)
TR (1)	TR199801511T2 (is)
WO (1)	WO1997028797A1 (is)
YU (1)	YU33298A (is)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7211582B1 (en)	1994-12-30	2007-05-01	Sepracor Inc.	Methods for treating urticaria using descarboethoxyloratadine
US7214683B1 (en)	1994-12-30	2007-05-08	Sepracor Inc.	Compositions of descarboethoxyloratadine
GB9723985D0 (en)	1997-11-14	1998-01-14	Zeneca Ltd	Pharmaceutical compositions
DK1041990T3 (da) *	1997-12-23	2006-10-02	Schering Corp	Præparat til behandling af respiratoriske sygdomme og hudsygdomme med mindst en leukotrien-antagonist og mindst et antihistamin
US6384038B1 (en) *	1998-04-14	2002-05-07	Sepracor Inc.	Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US6248308B1 (en)	1998-04-14	2001-06-19	Sepracor Inc.	Methods of using norastemizole in combination with leukotriene inhibitors to treat or prevent asthma
US6194431B1 (en)	1998-04-14	2001-02-27	Paul D. Rubin	Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
US6262066B1 (en)	1998-07-27	2001-07-17	Schering Corporation	High affinity ligands for nociceptin receptor ORL-1
ID29137A (id) *	1998-07-27	2001-08-02	Schering Corp	Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
PE20001070A1 (es) *	1998-09-10	2000-10-19	Schering Corp	Metodos y composiciones para tratar sinusitis, otitis media y otros desordenes relacionados usando antihistaminas
AU3924500A (en) *	1999-03-29	2000-10-16	Schering Corporation	Methods and compositions for treating allergic and related disorders using fluorinated descarboethoxyloratadine
DE10007203A1 (de)	2000-02-17	2001-08-23	Asta Medica Ag	Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
AU2002227240A1 (en) *	2000-10-30	2002-05-15	Schering Corporation	Treatment and method using loratadine and montelukast
US20020198228A1 (en) *	2001-04-03	2002-12-26	Kaura Sita R.	Composition and method for the treatment of respiratory desease
MY148466A (en) *	2001-10-26	2013-04-30	Merck Frosst Canada Ltd	Granule formulation
WO2004087095A2 (es) *	2003-03-31	2004-10-14	Osmotica Costa Rica, Sociedad Anonima	Dispositivo osmótico que contiene zafirlukast y un antagonista h1
EP1680084A2 (en) *	2003-10-21	2006-07-19	Direct-Haler A/S	A multiple route medication for the treatment of rhinitis and asthma
WO2005089748A1 (en) *	2004-03-17	2005-09-29	Pfizer Limited	Combination for treating inflammatory diseases
WO2006047427A1 (en)	2004-10-25	2006-05-04	Schering Corporation	M1 and/or m3 receptor antagonists in combination with other actives for treating respiratory disorders
TR200806298A2 (tr) *	2008-08-22	2010-03-22	Bi̇lgi̇ç Mahmut	Farmasötik formülasyon
CN102834406A (zh)	2009-06-16	2012-12-19	默沙东公司	作为糖皮质激素受体激动剂的新的[3.2-c]杂芳基甾体、其组合物和用途
KR101540191B1 (ko) *	2014-02-24	2015-07-28	성균관대학교산학협력단	로라타딘을 포함하는 항염증용 조성물
MA54707A (fr) *	2019-01-10	2021-11-17	Jiangyin Mucocare Pharmaceutical Co Ltd	Nouvelles formulations contenant des antagonistes des récepteurs des leucotriènes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4282233B1 (en) *	1980-06-19	2000-09-05	Schering Corp	Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
CA1261835A (en) *	1984-08-20	1989-09-26	Masaaki Toda	(fused) benz(thio)amides
GB8607294D0 (en) *	1985-04-17	1986-04-30	Ici America Inc	Heterocyclic amide derivatives
US5565473A (en) *	1990-10-12	1996-10-15	Merck Frosst Canada, Inc.	Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5270324A (en) *	1992-04-10	1993-12-14	Merck Frosst Canada, Inc.	Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
US5472964A (en) *	1992-12-22	1995-12-05	Merck Frosst Canada, Inc.	Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
US5595997A (en) *	1994-12-30	1997-01-21	Sepracor Inc.	Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine

1997
- 1997-02-04 IL IL12544697A patent/IL125446A0/xx unknown
- 1997-02-04 KR KR1019980706097A patent/KR19990082367A/ko not_active Withdrawn
- 1997-02-04 JP JP9528627A patent/JPH11504044A/ja active Pending
- 1997-02-04 EE EE9800234A patent/EE9800234A/xx unknown
- 1997-02-04 WO PCT/US1997/001799 patent/WO1997028797A1/en not_active Ceased
- 1997-02-04 AU AU22579/97A patent/AU732671B2/en not_active Ceased
- 1997-02-04 NZ NZ331160A patent/NZ331160A/xx unknown
- 1997-02-04 PL PL97328074A patent/PL328074A1/xx unknown
- 1997-02-04 EP EP97905757A patent/EP1014972A4/en not_active Withdrawn
- 1997-02-04 CN CN97192149A patent/CN1210465A/zh active Pending
- 1997-02-04 CA CA002245162A patent/CA2245162A1/en not_active Abandoned
- 1997-02-04 TR TR1998/01511T patent/TR199801511T2/xx unknown
- 1997-02-04 BR BR9707369A patent/BR9707369A/pt not_active Application Discontinuation
- 1997-02-04 SK SK1056-98A patent/SK105698A3/sk unknown
- 1997-02-04 CZ CZ982487A patent/CZ248798A3/cs unknown
1998
- 1998-07-22 IS IS4805A patent/IS4805A/is unknown
- 1998-08-05 BG BG102669A patent/BG102669A/bg unknown
- 1998-08-06 YU YU33298A patent/YU33298A/sr unknown
- 1998-08-07 NO NO983641A patent/NO983641L/no unknown

Also Published As

Publication number	Publication date
CZ248798A3 (cs)	1999-01-13
NO983641D0 (no)	1998-08-07
NO983641L (no)	1998-08-07
AU2257997A (en)	1997-08-28
TR199801511T2 (xx)	1998-10-21
PL328074A1 (en)	1999-01-04
CA2245162A1 (en)	1997-08-14
YU33298A (en)	1999-11-22
JPH11504044A (ja)	1999-04-06
KR19990082367A (ko)	1999-11-25
AU732671B2 (en)	2001-04-26
IS4805A (is)	1998-07-22
WO1997028797A1 (en)	1997-08-14
NZ331160A (en)	2000-07-28
SK105698A3 (en)	1999-05-07
EE9800234A (et)	1998-12-15
EP1014972A1 (en)	2000-07-05
CN1210465A (zh)	1999-03-10
BR9707369A (pt)	1999-07-20
IL125446A0 (en)	1999-03-12
EP1014972A4 (en)	2004-12-08

Publication	Publication Date	Title
BG102669A (bg)	1999-04-30	Метод за лечение и фармацевтичен състав
EP3054952B1 (en)	2022-10-26	Combinations of histone deacetylase 6 inhibitors and the her2 inhibitor lapatinib for use in the treatment of breast cancer
CA2315721C (en)	2008-08-12	Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
TWI389689B (zh)	2013-03-21	氟利本西林（ｆｌｉｂａｎｓｅｒｉｎ）於治療停經前性慾疾病之用途
US20080026054A1 (en)	2008-01-31	Novel anelgesic combination
HUP0204079A2 (hu)	2003-04-28	Szedatív hatástól mentes antihisztaminok és leukotrién hatást befolyásoló anyagok új kombinációja orrnyálkahártya-gyulladás, vagy kötőhártya-gyulladás kezelésére
CZ20023381A3 (cs)	2003-02-12	Kombinované farmaceutické prostředky obsahující antagonistu AT1-receptoru nebo/a inhibitor HMG-CoA reduktázy nebo/a ACE inhibitor
EP2136801A1 (en)	2009-12-30	Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome
EA003142B1 (ru)	2003-02-27	Лекарственное средство, обладающее антидепрессивным действием, его применение и способ лечения
JP2024507810A5 (is)	2025-02-26
WO2005004915A2 (en)	2005-01-20	Compositions comprising meloxicam
CN111093647A (zh)	2020-05-01	用于治疗共核蛋白病的他汀类组合物和方法
US20090118211A1 (en)	2009-05-07	Compositions and Methods for Enhancement of Sexual Function
US20050038018A1 (en)	2005-02-17	Meloxicam compositions
US4794112A (en)	1988-12-27	Acetaminophen/hydroxyzine analgesic combinations
IL292882A (en)	2022-07-01	Dosage of Bruton's tyrosine kinase inhibitor
US20070275996A1 (en)	2007-11-29	Use of Statins For The Treatment Of Metabolic Syndrome
EA022060B1 (ru)	2015-10-30	Соединение для лечения инфекционных заболеваний, соответствующий способ и фармацевтическая композиция, содержащая указанное соединение
EP4360631A1 (en)	2024-05-01	Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
US20240342155A1 (en)	2024-10-17	Hydroxychloroquine formulations, dosage forms, and methods of use
HK1018744A (en)	2000-01-07	Method of treatment and pharmaceutical composition
JPH10120592A (ja)	1998-05-12	メニエール病乃至メニエール症候群治療剤
HK40066392A (zh)	2022-08-19	Aerd/哮喘中的血栓烷受体拮抗剂
EP1377277B1 (en)	2008-08-06	Pharmaceutical compositions comprising pravastatin for reducing ldl cholesterol levels
US20130150375A1 (en)	2013-06-13	GEPIRONE-ER TREATMENT OF MAJOR DEPRESSION IN PATIENTS TAKING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)